Assessing changes in relapse rates in multiple sclerosis.
about
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosisRegression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Development of oral immunomodulatory agents in the management of multiple sclerosisPlacebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case dataOutcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.Rehabilitation interventions for the management of multiple sclerosis relapse: a short scoping review.Clinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.Risk stratification and mitigation multiple sclerosis.Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling toolThe Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse CareChanging EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression.Randomized study combining interferon and glatiramer acetate in multiple sclerosisVenous angioplasty in multiple sclerosis: neurological outcome at two years in a cohort of relapsing-remitting patients.Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.Statistical cures and other fallacies.Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis.Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.Can we measure long-term treatment effects in multiple sclerosis?Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS.Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.Time to first relapse as an endpoint in multiple sclerosis clinical trials.Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.Sample Size Estimation for Negative Binomial Regression Comparing Rates of Recurrent Events with Unequal Follow-Up Time.Defining and scoring response to IFN-β in multiple sclerosis.Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
P2860
Q24187126-5F4F75C2-AF55-462B-A7EA-ACABB857F097Q24188270-6BFA41F4-8E13-4FA2-B0AE-C0126242CBDAQ26798434-1F836107-5C1D-4FFD-9FA9-28755CF859F7Q26852672-3B37B249-3F6C-4CF7-9F66-64226261E4CDQ26998513-19C5EB17-B74A-441F-9B52-D7CDECFB9F87Q28388704-4CE431FA-8FF6-4EAC-88A5-78669800D086Q30000824-8AA6C59B-98CC-4B66-B331-B85A528BAD50Q33634866-8A71FC44-BB2A-4887-B82C-1760CD8FA095Q33931512-17B8AFF2-27D2-4B63-858A-1C27D686A06BQ34045441-EF6C28EE-B495-40B7-936E-31BCDB89ABBCQ34155446-2972D346-4F68-4843-8364-DBC561A5123CQ34729752-1C9149A7-2EB0-4FA4-B208-A61C623FFC88Q35649734-DDBDF0EF-A807-4AE1-92B8-34AA551D8F22Q35761200-3BC6A4CB-5E98-488E-9899-EFC00736DB16Q36780801-2B66703E-1F6F-44B4-BCBD-4333F4024079Q37267207-32C3F018-A2F8-40F6-9A37-5732872A169EQ37876566-620C0B89-F392-455E-85B3-EBF15A0FB0F0Q37964985-7FC4BD28-5E8A-43B9-AA45-09943285ACBEQ37987082-7DC213B0-BCA2-4923-9301-46A7C29E23BAQ37994162-68BD2449-1B17-47AA-A18E-0F00CF56C7B0Q38087504-D74853D5-8123-4605-BD34-CEC85A5FAAD1Q38298427-10F36683-F646-40DB-A961-5D9C336D1FF9Q38375605-084B0DC6-1624-40DA-9F6D-18E1BDC99DDDQ39024650-B50665CA-47CF-487D-B745-8BF2E87A6FCDQ39300217-6BA14C54-CD34-4D6B-96C1-84116759AB5AQ39565012-CF720EB4-787C-455B-A16C-F7574503B5ECQ45108872-65E9A75F-28FC-4F74-B90D-9854D87C9959Q45218637-E6AB0E37-4063-469C-9C36-CD40F6D06D6AQ46023940-8077525F-79FB-4FC7-BE45-53F76DB539EAQ47327274-2C166DBC-6D35-4CCB-AB4A-336D6DAF551FQ48922719-E4B39A07-39D5-46B9-A4B2-CD21F85A062C
P2860
Assessing changes in relapse rates in multiple sclerosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Assessing changes in relapse rates in multiple sclerosis.
@ast
Assessing changes in relapse rates in multiple sclerosis.
@en
type
label
Assessing changes in relapse rates in multiple sclerosis.
@ast
Assessing changes in relapse rates in multiple sclerosis.
@en
prefLabel
Assessing changes in relapse rates in multiple sclerosis.
@ast
Assessing changes in relapse rates in multiple sclerosis.
@en
P2093
P2860
P356
P1476
Assessing changes in relapse rates in multiple sclerosis.
@en
P2093
Gary R Cutter
Inmaculada B Aban
Maria P Sormani
Seidu Inusah
Solomon K Musani
Stacey S Cofield
Vinodh Srinivasasainagendra
P2860
P304
P356
10.1177/1352458510379246
P577
2010-09-01T00:00:00Z